Cumberland Pharmaceuticals (CPIX) Proxy Filing summary

Executive summary

• The annual meeting is scheduled for April 21, 2026, with shareholders voting on director elections, auditor ratification, executive compensation, and the frequency of future say-on-pay votes.

• Shareholders can vote electronically, by mail, or in person, with materials primarily distributed online to reduce costs and environmental impact.

• The company reported 20% revenue growth in 2025, significant increases in adjusted earnings and cash flow, and several product and clinical milestones.

• New equity financing of $5.4 million was raised, and the company expanded its product portfolio and international reach.

Voting matters and shareholder proposals

• Shareholders will vote on electing two directors, ratifying the appointment of Carr, Riggs & Ingram, L.L.C. as auditor, approving executive compensation, and determining the frequency of future say-on-pay votes.

• The board recommends voting for all proposals and for a triennial (every three years) say-on-pay vote.

• Shareholder proposals for the 2027 meeting must be received by November 12, 2026.

Board of directors and corporate governance

• The board consists of seven directors in three staggered classes, with two Class I directors up for election in 2026.

• All standing committees (Audit, Compensation, Governance & Nominating) are composed of independent directors.

• The board combines the roles of Chairman and CEO, with a Lead Independent Director providing additional oversight.

• The Governance Committee considers shareholder nominations and emphasizes ethics, experience, and commitment in director selection.